Williams C, Wickerhauser M, Busby T F, Ingham K C
Vox Sang. 1984;46(5):260-9. doi: 10.1111/j.1423-0410.1984.tb00085.x.
Conditions have been determined under which the C1 inactivator (C1-INA) can be pasteurized to reduce the risk of transfusion hepatitis associated with its use for replacement therapy in patients with genetic or acquired deficiencies. Recovery of 90% of the biological and immunological activity of a C1-INA concentrate was achieved following heat treatment for 10 h at 60 degrees C in the presence of 3 M potassium citrate. Crossed immunoelectrophoresis in heparinized agarose was used to demonstrate the ability of the pasteurized C1-INA to bind heparin and to form a precipitation pattern with antibody which was almost indistinguishable from that of an unheated control. High pressure liquid chromatography and enhancement of the fluorescence of 1,8-anilinonaphthalene sulfonate were used to show that other proteins present in the concentrate were also stabilized.
现已确定了一些条件,在这些条件下可对C1灭活剂(C1-INA)进行巴氏消毒,以降低在患有遗传性或获得性缺陷的患者中使用其进行替代疗法时与输血性肝炎相关的风险。在3M柠檬酸钾存在下于60℃热处理10小时后,C1-INA浓缩物的生物活性和免疫活性恢复了90%。在肝素化琼脂糖中进行交叉免疫电泳,以证明经巴氏消毒的C1-INA结合肝素并与抗体形成沉淀模式的能力,该沉淀模式与未加热对照的几乎无法区分。使用高压液相色谱法和增强1,8-苯胺基萘磺酸盐的荧光来表明浓缩物中存在的其他蛋白质也得到了稳定。